PDF herunterladen
Thromb Haemost 2002; 88(01): 56-59
DOI: 10.1055/s-0037-1613154
Review Article
Schattauer GmbH

Evaluation of Two Automated Methods for Measurement of the Ristocetin Cofactor Activity of von Willebrand Factor

Connie H. Miller
1   Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
,
S. Jean Platt
1   Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
,
Christine Daniele
2   Diagnostica Stago Inc., Parsippany, New Jersey, USA
,
Daniel Kaczor
2   Diagnostica Stago Inc., Parsippany, New Jersey, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 29. November 2001

Accepted after revision 21. März 2002

Publikationsdatum:
09. Dezember 2017 (online)

   Lizenzen und Reprints

Summary

We have evaluated two automated methods for measuring ristocetin cofactor activity (VWF:RCo) on an automated coagulation analyzer (STAR®, Diagnostica Stago Inc., Parsippany, NJ). A modification of the BC von Willebrand Reagent method (Dade Behring Inc., Newark, Delaware) was compared with a standard method using a platelet aggregometer, and an in-house automated method was developed using commercially available components. The STAR® measures the change in optical density (OD) caused by agglutination of platelets. Change in OD was linear for plasma dilutions between .25 and .04 U/mL. Coefficient of variation compared favorably with that of the standard method. In 123 normal women, the correlation coefficient (r) = .905. In menorrhagia cases, r = .901. In 20 VWD patients, r = .93. The CDC in-house method was compared to the BC Reagent method in 79 additional menorrhagia cases, with r = .94. The automated methods produced results equivalent or superior to those of traditional methods of measuring VWF:RCo.

Keywords

von Willebrand factor - ristocetin cofactor - methods
 

  • References

  • 1 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand disease. Blood 1987; 69: 454-9.
    PubMedSuche in Google Scholar
  • 2 Rodeghiero F, Castaman G, Tosetto A. von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type I von Willebrand disease – results based on an epidemiological investigation. Thromb Haemost 1990; 64: 349-52.
    Thieme ConnectPubMedSuche in Google Scholar
  • 3 Werner EJ, Abshire TC, Giroux DS, Tucker EL. The relative value of diagnostic studies for von Willebrand disease. J Pediatr 1992; 121: 34-8.
    CrossrefPubMedSuche in Google Scholar
  • 4 Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 2001; 07 Suppl: (Suppl. 01) 10-5.
    CrossrefPubMedSuche in Google Scholar
  • 5 Howard MA, Firkin BG. Ristocetin – a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-9.
    PubMedSuche in Google Scholar
  • 6 Dilley A, Drews C, Miller C, Lally C, Austin H, Ramaswamy D, Lurye D, Evatt B. Von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97: 630-6.
    PubMedSuche in Google Scholar
  • 7 Miller CH, Dilley A, Richardson L, Hooper WC, Evatt BL. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. Am J Hematol 2001; 67: 125-9.
    CrossrefPubMedSuche in Google Scholar
  • 8 Philipp CS, Dilley A, Miller CH, Bachman G, Siegel J, Evatt B, Saidi P. Platelet dysfunction and other hemostatic abnormalities among women with unexplained menorrhagia. Blood. 2000 96. (abstract).
    PubMedSuche in Google Scholar